Karen E. Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen E. Martin has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Andres Jose Garcia
Georgia Institute of Technology
5 shared publications - Christopher T. Johnson
Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA
2 shared publications - Edward Attah Botchwey
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, USA
2 shared publications Amy Y. Clark
Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA
1 shared publicationClaire A. McClain
Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA
1 shared publication- Dennis W. Zhou
Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA; Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA
1 shared publication
Latest Publications
- 24 April 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (9) , 680-693
Engineering immune-evasive allogeneic cellular immunotherapies
Allogeneic cellular immunotherapies hold a great promise for cancer treatment owing to their potential cost-effectiveness, scalability and on-demand availability. However, immune rejection of adoptively transferred allogeneic T and natural killer (NK) cells is a substantial obstacle to achieving clinical responses that are comparable to responses obtained with current autologous chimeric antigen receptor T cell therapies. In this Perspective, we discuss strategies to confer cell-intrinsic, immune-evasive properties to allogeneic T cells and NK cells in order to prevent or delay their immune rejection, thereby widening the therapeutic window. We discuss how common viral and cancer immune escape mechanisms can serve as a blueprint for improving the persistence of off-the-shelf allogeneic cell therapies. The prospects of harnessing genome editing and synthetic biology to design cell-based precision immunotherapies extend beyond programming target specificities and require careful consideration of innate and adaptive responses in the recipient that may curtail the biodistribution, in vivo expansion and persistence of cellular therapeutics.
- 24 April 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (9) , 680-693
Engineering immune-evasive allogeneic cellular immunotherapies
Allogeneic cellular immunotherapies hold a great promise for cancer treatment owing to their potential cost-effectiveness, scalability and on-demand availability. However, immune rejection of adoptively transferred allogeneic T and natural killer (NK) cells is a substantial obstacle to achieving clinical responses that are comparable to responses obtained with current autologous chimeric antigen receptor T cell therapies. In this Perspective, we discuss strategies to confer cell-intrinsic, immune-evasive properties to allogeneic T cells and NK cells in order to prevent or delay their immune rejection, thereby widening the therapeutic window. We discuss how common viral and cancer immune escape mechanisms can serve as a blueprint for improving the persistence of off-the-shelf allogeneic cell therapies. The prospects of harnessing genome editing and synthetic biology to design cell-based precision immunotherapies extend beyond programming target specificities and require careful consideration of innate and adaptive responses in the recipient that may curtail the biodistribution, in vivo expansion and persistence of cellular therapeutics.
- 25 May 2022
- Published by Elsevier in Biomaterials
- Vol. 286, 121601
Host type 2 immune response to xenogeneic serum components impairs biomaterial-directed osteo-regenerative therapies
- 25 May 2022
- Published by Elsevier in Biomaterials
- Vol. 286, 121601
Host type 2 immune response to xenogeneic serum components impairs biomaterial-directed osteo-regenerative therapies
- Top Cited Papers
- 26 March 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 133, 4-16
Macrophage phenotypes in tissue repair and the foreign body response: Implications for biomaterial-based regenerative medicine strategies
- 26 March 2021
- Published by Elsevier in Acta Biomaterialia
- Vol. 133, 4-16
Top Cited PapersMacrophage phenotypes in tissue repair and the foreign body response: Implications for biomaterial-based regenerative medicine strategies
- Open Access
- 28 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (35) , eaba5573
Immunotherapy via PD-L1–presenting biomaterials leads to long-term islet graft survival
Local biomaterial-mediated delivery of PD-L1 induces alloislet graft survival and function in a murine model of type 1 diabetes.
- 28 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (35) , eaba5573
Open AccessImmunotherapy via PD-L1–presenting biomaterials leads to long-term islet graft survival
Local biomaterial-mediated delivery of PD-L1 induces alloislet graft survival and function in a murine model of type 1 diabetes.
- Open Access
- 8 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Integrin-specific hydrogels modulate transplanted human bone marrow-derived mesenchymal stem cell survival, engraftment, and reparative activities
Stem cell therapies are limited by poor cell survival and engraftment. A hurdle to the use of materials for cell delivery is the lack of understanding of material properties that govern transplanted stem cell functionality. Here, we show that synthetic hydrogels presenting integrin-specific peptides enhance the survival, persistence, and osteo-reparative functions of human bone marrow-derived mesenchymal stem cells (hMSCs) transplanted in murine bone defects. Integrin-specific hydrogels regulate hMSC adhesion, paracrine signaling, and osteoblastic differentiation in vitro. Hydrogels presenting GFOGER, a peptide targeting α2β1 integrin, prolong hMSC survival and engraftment in a segmental bone defect and result in improved bone repair compared to other peptides. Integrin-specific hydrogels have diverse pleiotropic effects on hMSC reparative activities, modulating in vitro cytokine secretion and in vivo gene expression for effectors associated with inflammation, vascularization, and bone formation. These results demonstrate that integrin-specific hydrogels improve tissue healing by directing hMSC survival, engraftment, and reparative activities.
- 8 January 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Open AccessIntegrin-specific hydrogels modulate transplanted human bone marrow-derived mesenchymal stem cell survival, engraftment, and reparative activities
Stem cell therapies are limited by poor cell survival and engraftment. A hurdle to the use of materials for cell delivery is the lack of understanding of material properties that govern transplanted stem cell functionality. Here, we show that synthetic hydrogels presenting integrin-specific peptides enhance the survival, persistence, and osteo-reparative functions of human bone marrow-derived mesenchymal stem cells (hMSCs) transplanted in murine bone defects. Integrin-specific hydrogels regulate hMSC adhesion, paracrine signaling, and osteoblastic differentiation in vitro. Hydrogels presenting GFOGER, a peptide targeting α2β1 integrin, prolong hMSC survival and engraftment in a segmental bone defect and result in improved bone repair compared to other peptides. Integrin-specific hydrogels have diverse pleiotropic effects on hMSC reparative activities, modulating in vitro cytokine secretion and in vivo gene expression for effectors associated with inflammation, vascularization, and bone formation. These results demonstrate that integrin-specific hydrogels improve tissue healing by directing hMSC survival, engraftment, and reparative activities.
- Open Access
- 3 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (5) , eaaw1228
Lysostaphin and BMP-2 co-delivery reduces S. aureus infection and regenerates critical-sized segmental bone defects
Use of BMP-2 and lysostaphin-loaded hydrogels simultaneously clears S. aureus infection and repairs bone defects.
- 3 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (5) , eaaw1228
Open AccessLysostaphin and BMP-2 co-delivery reduces S. aureus infection and regenerates critical-sized segmental bone defects
Use of BMP-2 and lysostaphin-loaded hydrogels simultaneously clears S. aureus infection and repairs bone defects.